CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 8 No. 11
 

PEIT Improves Survival Rates in Hepatocellular Carcinoma

November 1, 1999

ORLANDO—At the Digestive Disease Week meeting, University of Tokyo researchers reported on the largest single-institution study of the use of percutaneous ethanol injection therapy (PEIT) in hepatocellular carcinoma (HCC). The research group studied 849 patients hospitalized for HCC at their institution between 1985 and 1997.

Although in the West, HCC occurs less often than metastatic liver disease, it is an important cause of death in many areas of Africa and Asia.

In an interview, University of Tokyo gastroenterologist Shuichiro Shiina, MD, said that HCC accounts for 95% of cases of primary liver cancer. “In Japan, 80% of liver cancer patients have cirrhosis,” Dr. Shiina said. “Seven percent of cirrhosis patients develop cancer within a year, and within 5 years, one third of all cirrhosis patients have cancer. Cirrhosis destroys so much of the liver that not much tissue can be removed to address the HCC. Furthermore, HCC often recurs even after ‘curative’ surgical resection.”

European and Japanese physicians have long employed PEIT to treat HCC. It involves the injection of ethanol through the skin and into the liver under the guidance of either computed tomography (CT) or ultrasound, usually the latter. The injections are repeated until the lesions are obliterated.

The researchers performed PEIT on 756 of the 849 HCC patients, who ranged in age from 35 to 87 years. PEIT was the sole treatment in 594 cases (79%). The remaining PEIT patients also underwent transcatheter arterial embolization.

Survival rates of all 756 PEIT patients at 1, 3, 5, and 10 years were 89%, 64%, 39%, and 18%, respectively. In the 349 patients who had three or fewer lesions (all of which were 3 cm or less in diameter), survival rates were higher: 93%, 74%, 47%, and 26%, respectively. In the 594 patients in whom all lesions were treated by PEIT, survival rates were 93%, 72%, 47%, and 24%, respectively.

“The Tokyo group no longer employs surgical resection for HCC patients,” Dr. Shiina said. “We repeat the PEIT injections until the tumor is totally destroyed. The median number of treatments we use is about six or seven.” Dr. Shiina added that side effects include fever, transient pain, and a feeling of alcohol(Drug information on alcohol) intoxication.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy